Amoy Diagnostics Approved to Market IVD for Lung Cancer

Amoy Diagnostics, a Xiamen maker of in vitro diagnostics, was given SFDA permission to market its EML4-ALK Fusion Gene Detection Kit in China. The assay detects 21 different fusion products from rearrangements of the EML4 and ALK genes. The activity of the EML4-ALK fusion oncogene, a recently discovered molecular target in non-small-cell lung cancer (NSCLC), can be inhibited by small-molecule inhibitors such as Xalkori from Pfizer. More details.... Stock Symbol: (NYSE: PFE) Share this with colleagues: // //